An update on brivaracetam for the treatment of pediatric partial epilepsy

Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis

(2020) Christian Brandt et al.   EPILEPSY & BEHAVIOR

Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label, follow‐up trial

(2020) Terence J. O’Brien et al.   EPILEPSIA

Mechanisms of action of currently used antiseizure drugs

(2020) Graeme J. Sills et al.   NEUROPHARMACOLOGY

Clinical experience with brivaracetam in a series of 46 children

(2020) Núria Visa-Reñé et al.   EPILEPSY & BEHAVIOR

A review of the drug−drug interactions of the antiepileptic drug brivaracetam

(2020) Brian D. Moseley et al.   EPILEPSY RESEARCH

Potential role of brivaracetam in pediatric epilepsy

(2020) Alberto Verrotti et al.   ACTA NEUROLOGICA SCANDINAVICA

Time course of drug-related treatment-emergent adverse side effects of brivaracetam

(2020) Kimford J. Meador et al.   EPILEPSY & BEHAVIOR

Pharmacokinetic considerations for anti-epileptic drugs in children

(2019) Alberto Verrotti et al.   Expert Opinion on Drug Metabolism & Toxicology

Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities

(2019) Evangelia Theochari et al.   EPILEPSY & BEHAVIOR

Brivaracetam for epilepsy

(2019) Van Hellerslia et al.   JAAPA-Journal of the American Academy of Physician Assistants

Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review

(2019) Francesco Brigo et al.   CNS DRUGS

Effects of cannabidiol on brivaracetam plasma levels

(2019) Kerstin A. Klotz et al.   EPILEPSIA

Use of intravenous brivaracetam in status epilepticus: A multicenter registry

(2019) Estevo Santamarina et al.   EPILEPSIA

Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus

(2019) Laurent Maximilian Willems et al.   EXPERT OPINION ON PHARMACOTHERAPY

Brivaracetam efficacy and safety in focal epilepsy

(2019) Yamane Makke et al.   Expert Review of Neurotherapeutics

Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study

(2019) Manuel Toledo et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients 

(2019) Edwin Liu et al.   PEDIATRIC DRUGS

Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials

(2019) Anup D. Patel et al.   EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY

Safety and Efficacy of Brivaracetam in Pediatric Refractory Epilepsy: A Single-Center Clinical Experience

(2019) Sara McGuire et al.   JOURNAL OF CHILD NEUROLOGY

Treatment with brivaracetam in children – The experience of a pediatric epilepsy center

(2019) Andreea Nissenkorn et al.   EPILEPSY & BEHAVIOR

Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials

(2019) Brian D. Moseley et al.   EPILEPSY RESEARCH

Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? — A case series

(2019) Bernhard J. Steinhoff et al.   EPILEPSY RESEARCH

The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection

(2019) Alberto Verrotti et al.   Expert Review of Neurotherapeutics

Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus

(2018) Adam Strzelczyk et al.   EPILEPSIA

Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model

(2018) Nathalie T. Sanon et al.   EPILEPSY & BEHAVIOR

Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program

(2018) Martin J. Brodie et al.   EPILEPSY RESEARCH

Pharmacokinetics and Drug Interaction of Antiepileptic Drugs in Children and Adolescents

(2018) Giulia Iapadre et al.   PEDIATRIC DRUGS

Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany

(2018) Laurent M. Willems et al.   Frontiers in Neurology

BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice

(2018) Vicente Villanueva et al.   ACTA NEUROLOGICA SCANDINAVICA

Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents

(2018) Susanne Schubert-Bast et al.   EPILEPSY & BEHAVIOR

Cannabinoids for epilepsy: What do we know and where do we go?

(2017) Martin J. Brodie et al.   EPILEPSIA

Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

(2017) Isabel Steinig et al.   EPILEPSIA

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years

(2017) Rik Schoemaker et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy

(2017) Emilio Russo et al.   Expert Opinion on Drug Discovery

Evaluation of brivaracetam: a new drug to treat epilepsy

(2017) Jasmina R. Milovanović et al.   EXPERT OPINION ON PHARMACOTHERAPY

Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures

(2017) John A. Kappes et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Brivaracetam and levetiracetam dose adjustments leading to behavioural adverse effects

(2017) May Yung Tiet et al.   POSTGRADUATE MEDICAL JOURNAL

New developments in the management of partial-onset epilepsy: role of brivaracetam

(2017) Giangennaro Coppola et al.   Drug Design Development and Therapy

Stereochemistry of the Brivaracetam Diastereoisomers

(2016) Shi Qiu et al.   CHIRALITY

Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures

(2016) Manuel Toledo et al.   EPILEPSIA

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

(2016) Henrik Klitgaard et al.   EPILEPSIA

Brivaracetam for the treatment of epilepsy

(2016) Pavel Klein et al.   EXPERT OPINION ON PHARMACOTHERAPY

Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures

(2016) Rik Schoemaker et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

(2015) Pavel Klein et al.   EPILEPSIA

An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam

(2015) Stephen L. Yates et al.   EPILEPSY & BEHAVIOR

Brivaracetam and carbamazepine interaction in healthy subjects and in vitro

(2015) Armel Stockis et al.   EPILEPSY RESEARCH

The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies

(2015) Xin Tian et al.   EXPERT OPINION ON PHARMACOTHERAPY

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays

(2013) V Daniels et al.   BRITISH JOURNAL OF PHARMACOLOGY

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial

(2013) Victor Biton et al.   EPILEPSIA

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial

(2013) Patrick Kwan et al.   EPILEPSIA

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial

(2012) Wim Van Paesschen et al.   EPILEPSIA

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Down-regulation Synaptic Vesicle Protein 2A in the Anterior Temporal Neocortex of Patients with Intractable Epilepsy

(2009) Guibo Feng et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men

(2008) Paul Rolan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY